Coronary artery disease is the major cause of death in the developed [url=http://www.selleckchem.com/screening-libraries.html]High Throughput Screening[/url] and an emerging health problem in developing countries. Ischaemic heart disease causes millions of deaths worldwide and remains the leading cause of [url=http://www.selleckchem.com/screening-libraries.html]Screening Libraries[/url] and mortality in the developed world. There have been major advances in preventing and treating atherosclerotic vascular [url=http://www.selleckchem.com/screening-libraries.html]Screening Library[/url]. However, many patients with ischemic coronary artery disease suffer from disabling symptoms despite intense [url=http://www.selleckchem.com/screening-libraries.html]Compound Libraries[/url] and are not eligible for invasive revascularization by angioplasty or [url=http://www.selleckchem.com/screening-libraries.html]compound library[/url].In such patients the challenge to improve blood flow to the ischemic heart has led to extensive research programs and numerous innovative approaches in the fields of molecular [url=http://www.selleckchem.com/screening-libraries.html]Chemical Libraries[/url], pharmacotherapy and newer mechanical technologies. These approaches include promoting the growth of new blood vessels in the [url=http://www.selleckchem.com/]kinase inhibitor[/url] using several potential compounds, delivery vectors, and delivery mechanisms to the ischemic myocardium. Studies, both in human and [url=http://www.selleckchem.com/]kinase inhibitors[/url] support the notion that various angiogenic growth factors and progenitor cells can enhance formation of new blood vessels. Progress in understanding the [url=http://www.selleckchem.com/pathways_PARP.html]parp inhibitor[/url] of angiogenesis, the isolation of angiogenic growth factors, successful preclinical studies, and [url=http://www.selleckchem.com/pathways_PARP.html]parp inhibitors[/url] early clinical trials have created great excitement about the potential of therapeutic angiogenesis.
The field of angiogenesis research was established almost 30 years ago by the Folkman hypothesis that tumor growth is [url=http://www.selleckchem.com/products/PLX-4032.html]PLX-4032[/url]. In the early 1970s, it became possible to culture vascular endothelial cells in vitro for the first time. [url=http://www.selleckchem.com/products/PLX-4032.html]Vemurafenib[/url] for angiogenesis were developed subsequently throughout that decade. The early 1980s saw the purification of the first angiogenic factors. The [url=http://www.selleckchem.com/products/PLX-4032.html]Zelboraf[/url] of the coronary collateral circulation has become increasingly clear over the past 20 years. Following experimental proof of [url=http://www.selleckchem.com/products/PF-2341066.html]Crizotinib[/url], the first promising results of therapeutic angiogenesis in humans were reported in severely symptomatic patients with critical limb [url=http://www.selleckchem.com/products/PF-2341066.html]PF-2341066[/url].